Celltrion Tops 90% Of Omlyclo Market

Celltrion is experiencing a significant surge in its market share with the autoimmune disease treatment 'Omlyclo', surpassing 90% in Spain as of June. The company's subsidiary in Spain was chosen as the supplier for the provincial government bids in four regions, including Catalonia, Basque Country, Asturias, and Valencia. This victory came after Omlyclo gained market acceptance as a treatment for chronic spontaneous urticaria and allergic asthma.

The key factor in Omlyclo's success has been its innovative 150mg autoinjector formulation, which is absent in the original product. Additionally, Omlyclo has demonstrated a relatively long shelf life and room temperature stability. To bolster its sales efforts, Celltrion is focusing on local medical professionals and pharmacy officials, highlighting the medical cost reduction benefits that arise from transitioning to biosimilars.

Ingesa, a bidding agency affiliated with the Spanish Ministry of Health, has also awarded Omlyclo and its counterpart 'Aptozma' in consecutive bids. Aptozma has now reached a majority market share in Spain as of the second quarter. Celltrion's sales strategy for Aptozma includes launching a 400mg formulation, which differentiates it from the original product.

Portugal is also witnessing similar success for Celltrion's autoimmune disease treatments. In the first half of the year, all autoimmune disease treatment products, including Remsima, Yuflyma, and Steqeyma, were awarded in the national bidding. Moreover, Omlyclo and the ophthalmic disease treatment Eydenzelt were listed among the successful bidders.

Celltrion's head in Spain, Kang Seok-hoon, anticipates that sales growth will accelerate further from the second half of the year, following the commencement of full-scale product supply and ongoing bidding successes for new products.